No Evidence of Long-Term Disruption of Glycometabolic Control After SARS-CoV-2 Infection.
No Evidence of Long-Term Disruption of Glycometabolic Control After SARS-CoV-2 Infection.
复制标题
DOI：
10.1210/clinem/dgab792
复制
发表时间：
2022-02-17
期刊：
影响因子：
--
通讯作者：
Piemonti L
中科院分区：
文献类型：
--
作者：
Laurenzi A;Caretto A;Molinari C;Mercalli A;Melzi R;Nano R;Tresoldi C;Rovere Querini P;Ciceri F;Lampasona V;Bosi E;Scavini M;Piemonti L
评估重症急性呼吸综合征冠状病毒2型肺炎期间诊断的血糖异常在感染解决后是否可能成为潜在的公共卫生问题。在一名疑似2019冠状病毒病（COVID-19）肺炎的成人队列中，我们将入院时的血糖数据与2019冠状病毒病前一年和出院后随访期间的空腹血糖（FBG）相结合。2020年2月25日至5月15日，意大利米兰圣拉斐尔医院收治了660名疑似COVID-19肺炎的成年人。通过结构化访谈/病历回顾，我们收集了入院时的人口统计、临床特征和实验室检查，以及住院期间或出院后和前一年的其他数据。入院时，我们根据美国糖尿病协会的标准将参与者分类为：(1)先前存在的糖尿病，(2)新诊断的糖尿病，(3)不在糖尿病范围内的高血糖，或(4)血糖正常。入院前和随访期间的空腹血糖分为正常或空腹血糖受损和糖尿病范围内的空腹血糖。在确诊的589例患者中，既往存在或新诊断的糖尿病、非糖尿病范围的高血糖和正常血糖的比例分别为19.6%、6.7%、43.7%和30.0%。与血糖正常的患者相比，与COVID-19相关的血糖异常患者炎症和器官损伤标志物增加，临床结果较差。感染消退后，血糖异常的发生率恢复到入院前的频率。与covid -19相关的血糖异常不太可能成为一个持久的公共卫生问题。关于COVID-19肺炎后糖尿病风险的危言耸听的说法应该谨慎解读。
To assess whether dysglycemia diagnosed during severe acute respiratory syndrome coronavirus 2 pneumonia may become a potential public health problem after resolution of the infection. In an adult cohort with suspected coronavirus disease 2019 (COVID-19) pneumonia, we integrated glucose data upon hospital admission with fasting blood glucose (FBG) in the year prior to COVID-19 and during postdischarge follow-up. From February 25 to May 15, 2020, 660 adults with suspected COVID-19 pneumonia were admitted to the San Raffaele Hospital (Milan, Italy). Through structured interviews/ medical record reviews, we collected demographics, clinical features, and laboratory tests upon admission and additional data during hospitalization or after discharge and in the previous year. Upon admission, we classified participants according to American Diabetes Association criteria as having (1) preexisting diabetes, (2) newly diagnosed diabetes, (3) hyperglycemia not in the diabetes range, or (4) normoglycemia. FBG prior to admission and during follow-up were classified as normal or impaired fasting glucose and fasting glucose in the diabetes range. In patients with confirmed COVID (n = 589), the proportion with preexisting or newly diagnosed diabetes, hyperglycemia not in the diabetes range and normoglycemia was 19.6%, 6.7%, 43.7%, and 30.0%, respectively. Patients with dysglycemia associated to COVID-19 had increased markers of inflammation and organs’ injury and poorer clinical outcome compared to those with normoglycemia. After the infection resolved, the prevalence of dysglycemia reverted to preadmission frequency. COVID-19–associated dysglycemia is unlikely to become a lasting public health problem. Alarmist claims on the diabetes risk after COVID-19 pneumonia should be interpreted with caution.
登录
查看更多内容
影响因子：
29
作者：
Coate KC;Cha J;Shrestha S;Wang W;Gonçalves LM;Almaça J;Kapp ME;Fasolino M;Morgan A;Dai C;Saunders DC;Bottino R;Aramandla R;Jenkins R;Stein R;Kaestner KH;Vahedi G;HPAP Consortium;Brissova M;Powers AC
通讯作者：
Powers AC
影响因子：
5.1
作者：
Goldman, Nina;Fink, Douglas;Davies, Zoe
通讯作者：
Davies, Zoe
影响因子：
20.8
作者：
Montefusco, Laura;Ben Nasr, Moufida;D'Addio, Francesca;Loretelli, Cristian;Rossi, Antonio;Pastore, Ida;Daniele, Giuseppe;Abdelsalam, Ahmed;Maestroni, Anna;Dell'Acqua, Marco;Ippolito, Elio;Assi, Emma;Usuelli, Vera;Seelam, Andy Joe;Fiorina, Roberta Maria;Chebat, Enrica;Morpurgo, Paola;Lunati, Maria Elena;Bolla, Andrea Mario;Finzi, Giovanna;Abdi, Reza;Bonventre, Joseph V.;Rusconi, Stefano;Riva, Agostino;Corradi, Domenico;Santus, Pierachille;Nebuloni, Manuela;Folli, Franco;Zuccotti, Gian Vincenzo;Galli, Massimo;Fiorina, Paolo
通讯作者：
Fiorina, Paolo
影响因子：
8.2
作者：
Lampasona V;Secchi M;Scavini M;Bazzigaluppi E;Brigatti C;Marzinotto I;Davalli A;Caretto A;Laurenzi A;Martinenghi S;Molinari C;Vitali G;Di Filippo L;Mercalli A;Melzi R;Tresoldi C;Rovere-Querini P;Landoni G;Ciceri F;Bosi E;Piemonti L
通讯作者：
Piemonti L
影响因子：
64.8
作者：
Al-Aly, Ziyad;Xie, Yan;Bowe, Benjamin
通讯作者：
Bowe, Benjamin